LPL Financial
IOVA icon

LPL Financial’s Iovance Biotherapeutics IOVA Stock Holding History

LPL Financial’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.75M Buy
661,075
+91,841
+16% +$349K ﹤0.01% 3394
2026
Q1 		$2M Sell
569,234
-53,838
-9% -$172K ﹤0.01% 3513
2025
Q4 		$1.7M Buy
623,072
+11,675
+2% +$27K ﹤0.01% 3548
2025
Q3 		$1.33M Buy
611,397
+127,070
+26% +$300K ﹤0.01% 3727
2025
Q2 		$833K Buy
484,327
+107,931
+29% +$269K ﹤0.01% 3914
2025
Q1 		$1.25M Buy
376,396
+125,689
+50% +$648K ﹤0.01% 3360
2024
Q4 		$1.86M Buy
250,707
+16,252
+7% +$151K ﹤0.01% 2928
2024
Q3 		$2.2M Sell
234,455
-9,384
-4% -$88.9K ﹤0.01% 2632
2024
Q2 		$1.96M Buy
243,839
+3,162
+1% +$33.9K ﹤0.01% 2622
2024
Q1 		$3.57M Buy
240,677
+111,541
+86% +$1.3M ﹤0.01% 2048
2023
Q4 		$1.05M Buy
129,136
+25,592
+25% +$134K ﹤0.01% 3006
2023
Q3 		$471K Buy
103,544
+29,108
+39% +$190K ﹤0.01% 3540
2023
Q2 		$524K Buy
74,436
+5,667
+8% +$40.6K ﹤0.01% 3406
2023
Q1 		$420K Buy
68,769
+7,950
+13% +$54.9K ﹤0.01% 3477
2022
Q4 		$389K Buy
60,819
+13,999
+30% +$109K ﹤0.01% 3466
2022
Q3 		$449K Sell
46,820
-1,194
-2% -$13.8K ﹤0.01% 3248
2022
Q2 		$530K Buy
48,014
+23,018
+92% +$302K ﹤0.01% 3147
2022
Q1 		$416K Buy
24,996
+5,929
+31% +$91.7K ﹤0.01% 3334
2021
Q4 		$364K Buy
19,067
+958
+5% +$21.1K ﹤0.01% 3548
2021
Q3 		$447K Buy
18,109
+1,865
+11% +$43.9K ﹤0.01% 3320
2021
Q2 		$423K Buy
+16,244
New +$422K ﹤0.01% 3295
2021
Q1 		– Sell
-5,465
Closed -$254K – 4119
2020
Q4 		$254K Sell
5,465
-1,404
-20% -$55.7K ﹤0.01% 3342
2020
Q3 		$226K Buy
+6,869
New +$211K ﹤0.01% 3113
2019
Q4 		– Sell
-25,097
Closed -$457K – 3372
2019
Q3 		$457K Buy
+25,097
New +$555K ﹤0.01% 2325

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

LPL Financial's IOVA Position: Q2 2026 in Review

LPL Financial increased its Iovance Biotherapeutics (IOVA) stake by 16% in Q2 2026, buying an estimated $349K and bringing the position to 661,075 shares worth $2.75M. The position accounts for ﹤0.01% of the portfolio, ranked #3394.

LPL Financial first reported a position in IOVA in Q3 2019 and has held it in 24 quarters since. The position peaked at $3.57M in Q1 2024. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • LPL Financial held 661,075 shares of Iovance Biotherapeutics worth $2.75M as of Q2 2026.
  • LPL Financial bought 91,841 Iovance Biotherapeutics shares in Q2 2026, an estimated $349K.
  • Iovance Biotherapeutics made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #3394 holding.
  • LPL Financial first reported a position in Iovance Biotherapeutics in Q3 2019 and has held it in 24 quarters since.
  • LPL Financial's Iovance Biotherapeutics position peaked at $3.57M in Q1 2024.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.